| Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. | lymphoma, |
| Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. | oral |
| REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. | lymphoma, |
| The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. | lymphoma,leukemia, |
| The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. | None |
| Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein. | None |
| Dendritic cells conditionally transformed by v-relER oncogene express lymphoid marker genes. | None |
| X-ray crystal structure of proto-oncogene product c-Rel bound to the CD28 response element of IL-2. | None |
| A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein. | None |
| Differential regulation of the inhibitor of apoptosis ch-IAP1 by v-rel and the proto-oncogene c-rel. | None |
| The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation. | None |
| Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes. | None |
| The RxxRxRxxC motif conserved in all Rel/kappa B proteins is essential for the DNA-binding activity and redox regulation of the v-Rel oncoprotein. | None |
| The v-rel oncogene of avian reticuloendotheliosis virus transforms immature and mature lymphoid cells of the B cell lineage in vitro. | None |
| Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor. | None |
| Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL. | None |
| CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel. | None |
| this study identifies CAPERalpha (RNA binding motif protein 39) as a new transcriptional coregulator for v-Rel and reveals an important role in modulating Rel_s oncogenic activity. | None |
| Molecular mechanisms of transformation by the v-rel oncogene. | None |
| A member of the set of kappa B binding proteins, HIVEN86A, is a product of the human c-rel proto-oncogene. | None |